| Summary of Net Loss Related To Segment Expenses |
The following table presents information about reported segment revenues, significant segment expenses, and segment loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Collaboration revenue |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
7,500 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
Direct external research and development costs: |
|
|
|
|
|
|
|
|
|
|
|
|
Azetukalner |
|
|
55,760 |
|
|
|
43,405 |
|
|
|
102,833 |
|
|
|
74,906 |
|
Pain programs |
|
|
5,582 |
|
|
|
925 |
|
|
|
9,973 |
|
|
|
1,977 |
|
Pre-clinical, discovery and other programs |
|
|
4,683 |
|
|
|
5,186 |
|
|
|
7,641 |
|
|
|
9,101 |
|
Personnel-related expenses |
|
|
27,731 |
|
|
|
22,386 |
|
|
|
56,741 |
|
|
|
45,026 |
|
Stock-based compensation expense |
|
|
16,732 |
|
|
|
13,713 |
|
|
|
33,626 |
|
|
|
25,887 |
|
Other research and development costs |
|
|
4,642 |
|
|
|
2,600 |
|
|
|
8,843 |
|
|
|
6,025 |
|
Other general and administrative costs |
|
|
8,025 |
|
|
|
6,014 |
|
|
|
15,826 |
|
|
|
11,545 |
|
Interest income |
|
|
(12,145 |
) |
|
|
(7,199 |
) |
|
|
(19,052 |
) |
|
|
(15,282 |
) |
Other segment items(1) |
|
|
(274 |
) |
|
|
(2,324 |
) |
|
|
(3,393 |
) |
|
|
(1,932 |
) |
Net loss |
|
$ |
(110,736 |
) |
|
$ |
(84,706 |
) |
|
$ |
(213,038 |
) |
|
$ |
(149,753 |
) |
(1)Other segment items include foreign exchange gain (loss) and income tax recovery.
|